Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
101 studies found for:    Gd-DTPA
Show Display Options
Rank Status Study
1 Completed
Has Results
Multihance at 3 Tesla in Brain Tumors
Condition: Brain Tumor
Interventions: Drug: Multihance;   Drug: Arm 2 - Magnevist
2 Active, not recruiting Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
Condition: Liver Tumor
Interventions: Drug: MRI with Multihance;   Drug: MRI with Eovist
3 Terminated
Has Results
Safety and Efficacy of MultiHance in Pediatric Patients
Condition: Central Nervous System Diseases
Intervention: Drug: gadobenate dimeglumine
4 Completed Magnevist Post-marketing Surveillance in Japan
Condition: Diagnostic Imaging
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
5 Completed
Has Results
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Conditions: Fibrosis;   Kidney Failure;   Renal Insufficiency
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
6 Completed Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI
Condition: Hepatocellular Carcinoma
Intervention: Drug: gadobenate dimeglumine (MultiHance)
7 Completed Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the Brain
Condition: Brain Lesions
Interventions: Drug: MULTIHANCE:;   Drug: GADOVIST
8 Completed Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Conditions: Magnetic Resonance Angiography;   Peripheral Vascular Diseases;   Peripheral Arterial Diseases
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
9 Completed Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis
Condition: Brain Neoplasms
Intervention: Drug: Magnevist (SH L 451A)
10 Active, not recruiting Crossover Comparison of MultiHance and Dotarem
Condition: Brain Disease
Interventions: Drug: Gadobenate;   Drug: Gadoterate
11 Completed Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries
Condition: Carotid, Aortic, Renal or Peripheral Artery Disease
Interventions: Drug: Gadobenate Dimeglumine;   Drug: Gadopentetate Dimeglumine
12 Recruiting Liver Lesions in Contrast-Enhanced Magnetic Resonance Imaging (MRI)
Condition: Liver Neoplasms
Interventions: Drug: Gadoxetate;   Drug: Gadopentetate Dimeglumine
13 Completed
Has Results
Contrast-enhanced MRI in Children 2 Months to <2 Years
Condition: Magnetic Resonance Imaging
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-6661)
14 Completed Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries
Condition: Peripheral Vascular Disease
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
15 Enrolling by invitation Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?
Condition: Meniere Disease
Intervention: Drug: Gadopentetate dimeglumine
16 Completed Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects
Condition: Healthy
Interventions: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882);   Drug: Moxifloxacin (BAY12-8039);   Drug: Placebo
17 Recruiting Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer
Conditions: Cardiovascular Injury;   Prostate Carcinoma
Interventions: Procedure: Magnetic Resonance Imaging;   Behavioral: Exercise Intervention;   Radiation: Gadopentetate Dimeglumine;   Procedure: Perfusion Magnetic Resonance Imaging;   Procedure: Spectroscopy;   Other: Laboratory Biomarker Analysis
18 Completed Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries
Condition: Stenosis
Intervention: Drug: Gadopentetate dimeglumine (Magnevist)
19 Completed A Pharmacokinetics Study of MultiHance in Pediatric Patients
Condition: Central Nervous System Pathology
Intervention: Drug: Multihance
20 Completed Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches
Condition: Cardiovascular Abnormalities
Intervention: Drug: Gadopentetate dimeglumine (Magnevist)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years